Tena, thanks for posting this information. I am bumping the prior post by including the following information.

Perry Cohen and I are both possible candidates for the trial that is based in Philadelphia.

Cross posted from http://neurotalk.psychcentral.com/sh...light=ceregene

PDTrials.org
Study of CERE-120 in People with Parkinson’s Disease
Official Study Title: Randomized, Double-Blind, Sham Surgery-Controlled Study of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) to Assess the Efficacy and Safety of Bilateral Intraputaminal (IPu) Delivery in Subjects with Idiopathic Parkinson’s Disease
http://www.pdtrials.org/front/trial_...p?trial_id=128


ClinicalTrials.gov
Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 For Efficacy and Safety in Subjects With Idiopathic Parkinson's Disease
This study is currently recruiting patients.
Verified by Ceregene March 2007
http://clinicaltrials.gov/show/NCT00400634


Recombinate DNA Advisory Committee
Meeting Minutes
September 2006
http://www4.od.nih.gov/oba/RAC/minut...utes_09-06.pdf



PowerPoint Presentation
CERE-120 (AAV-Neurturin) for Parkinson’s Disease
NIH OBA Protocol # 0501-689
A Phase I, Open-Label Study of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN] to Assess the Safety and Tolerability of Intrastriatal Delivery to Subjects with Idiopathic Parkinson's Disease
http://www.webconferences.com/nihoba...des16Mar05.pdf